Casey M Cosgrove, MD
Academic Title: Assistant Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a gynecologic oncologist who specializes in treating patients with endometrial, uterine, ovarian, vulvar, cervical and peritoneal cancers, as well as gestational trophoblastic disease. I am passionate about providing comprehensive care to my patients, including complex and minimally invasive surgery, chemotherapy and survivorship, and enjoy building relationships with them and their families through open and honest communication. The care at the OSUCCC – James is special because of the large multidisciplinary team of physicians, nurses and ancillary services like social workers, patient care resource managers, nutritionists, geneticists and many more. At The James, my patients have access to the most innovative and exciting clinical trials, which offer more and potentially better options for their care. I also have access to the most up-to-date surgical techniques and equipment. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research is dedicated to evaluating prognostic biomarkers in endometrial cancer, as well as identifying tumor microenvironmental features that may be predictive or prognostic. The identification of these molecular features may lead to modifications in treatment planning in a clinical setting. I also have an interest in clinical research in clinical trials, surgical and pathology of gynecological cancers as well as hereditary cancer syndromes. In addition to my clinical work, I am an assistant professor in the Department of Gynecologic Oncology at The Ohio State University College of Medicine, where I teach both residents and medical students. I am also a member of several professional organizations, including the Society of Gynecologic Oncology and the American College of Obstetrics and Gynecology. The OSUCCC – James is a great place to work. The facilities are beautiful, and I enjoy the amazing group of people who help me to provide care to our patients each day. At The James, I am able to participate in groundbreaking research and contribute to our shared goal of creating a cancer-free world.
Clinical Expertise
More info for- Endometrial Cancers
- Ovarian Cancers
- Vulvar Cancers
- Uterine Cancers
- Robotics
- Peritoneal Cancers
Where I See Patients
More info forStefanie Spielman Comprehensive Breast Center
1145 Olentangy River Road Columbus, Ohio 43212 800-293-5066 Location InformationEducation & Training
More info forMedical School
- Florida State University College of Medicine
A2500 University Center, Tallahassee, FL
Fellowship - Gynecologic Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Residency - Obstetrics & Gynecology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
- Florida State University College of Medicine
Academic Office & Contact Information
More info forAcademic Office:
Starling Loving Hall
320 W 10th Ave
Columbus, Ohio 43210-1280Phone:
614-293-8512Email:
cosgrove.38@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Videos
More info forPublications
More info forOctober 22, 2024Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
Haight PJ, Lammers S, Kistenfeger Q, Leipold C, Suarez AA, Tozbikian GH, Esnakula A, Cosgrove C, Bixel KL
Gynecol Oncol
October 16, 2024Obesity-induced extracellular vesicles proteins drive the endometrial cancer pathogenesis: therapeutic potential of HO-3867 and Metformin.
Sakaue T, Dorayappan KDP, Zingarelli R, Khadraoui W, Anbalagan M, Wallbillich J, Bognar B, Wanner R, Cosgrove C, Suarez A, Koga H, Maxwell GL, O'Malley DM, Cohn DE, Selvendiran K
Oncogene
August 1, 2024Recurrent malignant struma ovarii presenting as peritoneal carcinomatosis in the setting of an intact thyroid: A case report and review of the literature.
Brown M, Haight P, Ringel M, Phay J, Esnakula A, Vazzano J, Cosgrove C
Gynecol Oncol Rep
June 28, 2024Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
Meade CE, Sinnott JA, Backes FJ, Cosgrove CM, Quick AM, Trabert B, Plascak JJ, Felix AS
Gynecol Oncol
April 25, 2024Bridging the Gap from Bench to Bedside: A Call for In Vivo Preclinical Models to Advance Endometrial Cancer and Cervical Cancer Immuno-Oncology Research.
Chambers L, Haight P, Chalif J, Mehra Y, Spakowicz D, Backes FJ, Cosgrove CM, O'Malley DM, Vargas R, Corr BR, Bae-Jump VL, Arend RC
Clin Cancer Res
April 8, 2024Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Kopelman ZA, Tian C, Tumas J, Phippen NT, Tarney CM, Hope ER, Winkler SS, Jokajtys S, Kucera CW, Chan JK, Richardson MT, Kapp DS, Hamilton CA, Leath CA, Jones NL, Rocconi RP, Farley JH, Secord AA, Cosgrove CM, Powell MA, Klopp A, Walker JL, Fleming GF, Bateman NW, Conrads TP, Maxwell GL, Darcy KM
Gynecol Oncol
March 2, 2024Reply to "Mismatch repair and microsatellite instability-Recommendation for an optimal test strategy".
Riedinger CJ, Esnakula A, Haight PJ, Suarez AA, Chen W, Gillespie J, Villacres A, Chassen A, Cohn DE, Goodfellow PJ, Cosgrove CM
Cancer
January 24, 2024Changes in prospectively collected patient-reported outcomes among women with incident endometrial cancer.
Sinnott JA, Torkashvand E, Meade CE, Salani R, Vetter MH, Hall B, Skolnick R, Bixel KL, Cohn DE, Cosgrove CM, Copeland LJ, Hebert C, Felix AS
J Cancer Surviv
January 22, 2024Does the choice of platinum doublet matter? A study to evaluate the impact of platinum doublet choice for treatment of platinum-sensitive ovarian cancer recurrence on the development of future PARP inhibitor and platinum resistance.
Levine MD, Wang H, Sriram B, Khan A, Senter L, McLaughlin EM, Bixel KL, Chambers LM, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Backes FJ
Gynecol Oncol
January 1, 2024Case report: Characterization of the immunologic and molecular landscape in a unique presentation of invasive lobular carcinoma with concurrent uterine carcinosarcoma treated with immunotherapy.
Riedinger CJ, Eisele CD, Esnakula A, Stover DG, Freud AG, Cosgrove CM
Front Immunol
December 7, 2023Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T, Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups
N Engl J Med
September 26, 2023Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
Riedinger CJ, Esnakula A, Haight PJ, Suarez AA, Chen W, Gillespie J, Villacres A, Chassen A, Cohn DE, Goodfellow PJ, Cosgrove CM
Cancer
September 23, 2023TP53 mutation and abnormal p53 expression in endometrial cancer: Associations with race and outcomes.
Whelan K, Dillon M, Strickland KC, Pothuri B, Bae-Jump V, Borden LE, Thaker PH, Haight P, Arend RC, Ko E, Jackson AL, Corr BR, Ayoola-Adeola M, Wright JD, Podwika S, Smitherman C, Thomas S, Lightfoot M, Newton M, Washington C, Mullen M, Cosgrove C, Harsono AAH, Powell K, Herzog TJ, Salani R, Alvarez Secord A
Gynecol Oncol
September 21, 2023The impact of antibiotic and proton pump inhibitor use at the time of adjuvant platinum-based chemotherapy on survival in patients with endometrial cancer.
Haight PJ, Kistenfeger Q, Riedinger CJ, Khadraoui W, Backes FJ, Bixel KL, Copeland LJ, Cohn DE, Cosgrove CM, O'Malley DM, Nagel CI, Spakowicz DJ, Chambers LM
Gynecol Oncol
August 25, 2023Mixed clear cell/endometrioid and clear cell/serous carcinoma of the uterus are clinicopathologically similar to pure clear cell carcinoma: An NRG Oncology/Gynecologic Oncology Group (GOG-210) study of 311 women.
Hagemann IS, Deng W, Zaino RJ, Powell MA, Gunderson Jackson C, Cosgrove C, Mathews C, Pearl ML, Waggoner S, Ghebre R, Lele S, Guntupalli S, Secord AA, Ioffe O, Rasty G, Singh M, Soslow R, Creasman W, Mutch DG
Gynecol Oncol
April 8, 2023Glassy cell carcinoma of the cervix: Findings from a combined National Cancer Database analysis and single institution review of treatment patterns and outcomes.
Levine MD, Barrington DA, Meade CE, Lammers SM, McLaughlin EM, Suarez AA, Backes FJ, Copeland LJ, O'Malley DM, Cosgrove CM, Cohn DE, Nagel CI, Felix AS, Bixel KL
Gynecol Oncol
April 6, 2023Mismatch Repair Protein Status of Non-Neoplastic Uterine and Intestinal Mucosa in Patients with Lynch Syndrome and Double Somatic Mismatch Repair Protein Mutations.
Freitag CE, Chen W, Pearlman R, Hampel H, Stanich PP, Cosgrove CM, Konnick EQ, Pritchard CC, Frankel WL
Hum Pathol
April 1, 2023Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer.
Piver RN, Wagner VM, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Gynecol Oncol Rep
April 1, 2023Recurrence rate in early-stage epithelial ovarian cancer: Is there a role for upfront maintenance with PARP inhibitors in stages I and II?
Levine MD, O'Malley DM, Haight PJ, Senter L, Wagner V, Bixel KL, Cohn DE, Copeland LJ, Cosgrove CM, McLaughlin EM, Backes FJ
Gynecol Oncol Rep
January 1, 2023Epigenetic MMR defect identifies a risk group not accounted for through traditional risk stratification algorithms in endometrial cancer.
Riedinger CJ, Brown M, Haight PJ, Backes FJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Front Oncol
December 24, 2022Postoperative Venous Thromboembolism Risk Stratification in Patients with Uterine Cancer.
Wagner VM, Piver RN, Levine MD, Backes FJ, Chambers LJ, Cohn DE, Copeland LJ, Cosgrove CM, Nagel CI, O'Malley DM, Bixel KL
Am J Obstet Gynecol
October 6, 2022Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers.
Hakkaart C, Pearson JF, Marquart L, Dennis J, Wiggins GAR, Barnes DR, Robinson BA, Mace PD, Aittomäki K, Andrulis IL, Arun BK, Azzollini J, Balmaña J, Barkardottir RB, Belhadj S, Berger L, Blok MJ, Boonen SE, Borde J, Bradbury AR, Brunet J, Buys SS, Caligo MA, Campbell I, Chung WK, Claes KBM, GEMO Study Collaborators , EMBRACE Collaborators , Collonge-Rame MA, Cook J, Cosgrove C, Couch FJ, Daly MB, Dandiker S, Davidson R, de la Hoya M, de Putter R, Delnatte C, Dhawan M, Diez O, Ding YC, Domchek SM, Donaldson A, Eason J, Easton DF, Ehrencrona H, Engel C, Evans DG, Faust U, Feliubadaló L, Fostira F, Friedman E, Frone M, Frost D, Garber J, Gayther SA, Gehrig A, Gesta P, Godwin AK, Goldgar DE, Greene MH, Hahnen E, Hake CR, Hamann U, Hansen TVO, Hauke J, Hentschel J, Herold N, Honisch E, Hulick PJ, Imyanitov EN, SWE-BRCA Investigators , kConFab Investigators , HEBON Investigators , Isaacs C, Izatt L, Izquierdo A, Jakubowska A, James PA, Janavicius R, John EM, Joseph V, Karlan BY, Kemp Z, Kirk J, Konstantopoulou I, Koudijs M, Kwong A, Laitman Y, Lalloo F, Lasset C, Lautrup C, Lazaro C, Legrand C, Leslie G, Lesueur F, Mai PL, Manoukian S, Mari V, Martens JWM, McGuffog L, Mebirouk N, Meindl A, Miller A, Montagna M, Moserle L, Mouret-Fourme E, Musgrave H, Nambot S, Nathanson KL, Neuhausen SL, Nevanlinna H, Yie JNY, Nguyen-Dumont T, Nikitina-Zake L, Offit K, Olah E, Olopade OI, Osorio A, Ott CE, Park SK, Parsons MT, Pedersen IS, Peixoto A, Perez-Segura P, Peterlongo P, Pocza T, Radice P, Ramser J, Rantala J, Rodriguez GC, Rønlund K, Rosenberg EH, Rossing M, Schmutzler RK, Shah PD, Sharif S, Sharma P, Side LE, Simard J, Singer CF, Snape K, Steinemann D, Stoppa-Lyonnet D, Sutter C, Tan YY, Teixeira MR, Teo SH, Thomassen M, Thull DL, Tischkowitz M, Toland AE, Trainer AH, Tripathi V, Tung N, van Engelen K, van Rensburg EJ, Vega A, Viel A, Walker L, Weitzel JN, Wevers MR, Chenevix-Trench G, Spurdle AB, Antoniou AC, Walker LC
Commun Biol
October 5, 2022ASO Visual Abstract: Racial Disparities in Surgical Outcomes Among Women with Endometrial Cancer.
Felix AS, Nafiu T, Cosgrove CM, Ewing AP, Mpody C
Ann Surg Oncol
September 22, 2022Racial Disparities in Surgical Outcomes Among Women with Endometrial Cancer.
Felix AS, Nafiu T, Cosgrove CM, Ewing AP, Mpody C
Ann Surg Oncol
September 22, 2022The contemporary presentation and diagnosis of endometrial cancer recurrence: When, where, and how?
Riedinger CJ, Patterson JM, Backes FJ, O'Malley D, Bixel KL, Copeland LJ, Cohn DE, Goodfellow PJ, Cosgrove CM
Gynecol Oncol
August 2, 2022Less is more: Clinical utility of postoperative labs following minimally invasive hysterectomy for endometrial cancer.
Lightfoot MDS, Felix AS, Calo CA, Hosmer-Quint JT, Taylor KL, Brown MB, Salani R, Copeland LJ, O'Malley DM, Bixel KL, Cohn DE, Fowler JM, Backes FJ, Cosgrove CM
Am J Obstet Gynecol
August 1, 2022High pre-treatment neutrophil-to-lymphocyte ratio as a prognostic marker for worse survival in patients with recurrent/metastatic cervical cancer treated with immune checkpoint inhibitors.
Calo CA, Barrington DA, Brown M, Gonzalez L, Baek J, Huffman A, Benedict J, Backes F, Chambers L, Cohn D, Copeland L, Cosgrove C, Nagel C, O'Malley D, Bixel K
Gynecol Oncol Rep
July 23, 2022Racial and ethnic disparities in readmission risk following the surgical management of endometrial cancer.
Barrington DA, Meade CE, Cosgrove CM, Cohn DE, Felix AS
Gynecol Oncol
June 3, 2022TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.
Thiel KW, Devor EJ, Filiaci VL, Mutch D, Moxley K, Alvarez Secord A, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Aghajanian C, Samuelson MI, Lankes HA, Soslow RA, Leslie KK
J Clin Oncol
June 1, 2022An investigation into human papillomavirus (HPV) vaccination for patients undergoing surgery for high-grade cervical or vulvar dysplasia.
Boyles GP, Baek J, Pandit R, Cosgrove CM, Bixel KL
Gynecol Oncol Rep
January 5, 2022Hospital-based ovarian cancer patient traceback program results in minimal genetic testing uptake.
Weinmann S, Phillips S, Sweet K, Cosgrove CM, Senter L
Gynecol Oncol
January 1, 2022Endometrial cancer: molecular classification and future treatments.
Corr B, Cosgrove C, Spinosa D, Guntupalli S
BMJ Med
November 1, 2021Up-Front Multigene Panel Testing for Cancer Susceptibility in Patients With Newly Diagnosed Endometrial Cancer: A Multicenter Prospective Study.
Levine MD, Pearlman R, Hampel H, Cosgrove C, Cohn D, Chassen A, Suarez A, Barrington DA, McElroy JP, Waggoner S, Nakayama J, Billingsley C, Resnick K, Andrews S, Singh S, Jenison E, Clements A, Neff R, Goodfellow PJ, Ohio Prevention and Treatment of Endometrial Cancer Initiative Study Group
JCO Precis Oncol
November 1, 2021Wound complications following vulvar excision for nonmalignant lesions.
Boyles GP, Weaver AM, Cohn DE, Backes FJ, Copeland LJ, Bixel KL, Fowler JM, O'Malley DM, Cosgrove CM
AJOG Glob Rep
October 29, 2021Aberrant expression of TMEM205 signaling promotes platinum resistance in ovarian cancer: An implication for the antitumor potential of DAP compound.
Calo CA, Smith BQ, Dorayappan KDP, Saini U, Lightfoot M, Wagner V, Kalaiyarasan D, Cosgrove C, Wang QE, Maxwell GL, Kálai T, Kuppusamy P, Cohn DE, Selvendiran K
Gynecol Oncol
August 17, 2021Endometrial Cancer: Who lives, who dies, can we improve their story?
Cosgrove CM, Backes FJ, O'Malley D, Bixel KL, Suarez AA, Fowler JM, Copeland LJ, Goodfellow PJ, Cohn DE
Oncologist
July 13, 2021Phase I evaluation of lenvatinib and weekly paclitaxel in patients with recurrent endometrial, ovarian, fallopian tube, or primary peritoneal Cancer.
Backes FJ, Wei L, Chen M, Hill K, Dzwigalski K, Poi M, Phelps M, Salani R, Copeland LJ, Fowler JM, Cohn DE, Bixel K, Cosgrove C, Hays J, O'Malley D
Gynecol Oncol
May 3, 2021Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.
Cosgrove CM, Barrington D, Backes FJ
Curr Oncol Rep
February 1, 2021Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.
Leslie KK, Filiaci VL, Mallen AR, Thiel KW, Devor EJ, Moxley K, Richardson D, Mutch D, Secord AA, Tewari KS, McDonald ME, Mathews C, Cosgrove C, Dewdney S, Casablanca Y, Jackson A, Rose PG, Zhou X, McHale M, Lankes H, Levine DA, Aghajanian C
Gynecol Oncol
January 7, 2021The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.
Hagemann IS, Deng W, Zaino RJ, Powell MA, Gunderson C, Cosgrove C, Mathews C, Pearl ML, Waggoner S, Ghebre R, Lele S, Guntupalli S, Secord AA, Ioffe O, Park K, Rasty G, Singh M, Soslow R, Creasman W, Mutch DG
Gynecol Oncol
January 1, 2021Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients.
Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D, Yilmaz A, Chen W, Frankel WL, Suarez AA, Cosgrove C, Backes F, Copeland L, Fowler J, O'Malley D, Salani R, McElroy JP, Stanich PP, Goodfellow P, Cohn DE
Gynecol Oncol
September 1, 2020Pathologic chemotherapy response score in epithelial ovarian cancer: Surgical, genetic, and survival considerations.
Barrington DA, Felix AS, Owda R, Suarez AA, Cohen DW, Senter L, Copeland LJ, Fowler JM, Backes FJ, Cohn DE, Bixel KL, O'Malley DM, Salani R, Cosgrove CM
Surg Oncol
June 9, 2020Where you live matters: A National Cancer Database study of Medicaid expansion and endometrial cancer outcomes.
Barrington DA, Sinnott JA, Calo C, Cohn DE, Cosgrove CM, Felix AS
Gynecol Oncol
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Cosgrove has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- GlaxoSmithKline
- UpToDate
- Intuitive Surgical Inc.
- GOG Foundation, Inc.
Patient Comments
Excellent
Dr Cosgrove and staff were excellent
Very informative, courteous. Professional
Super star
Love Doctor Cosgrove,his nurse practitioner Tara is very good too!
Dr. Cosgrove is always professional and compassionate.
Excellent Dr. Cosgrove
Dr Cosgrove is the best!!
Dr. Cosgrove keeps me informed with my treatments.
Dr. Cosgrove is professional and personable. He is extremely knowledgeable about my condition. He puts me at ease.
Dr Cosgrove is an amazing doctor. I would highly recommend him to any and all my friends and family members!!
I always feel likes I'm treated as an individual not as just another case.
Dr. Cosgrove and Tara are the best you could ask for!
Dr Cosgrove is very patient and detailed in his explanations without being alarming. He has wonderful patient communication and mannerisms
Very happy with my care at OSU
Love Dr. Cosgrove and staff!
I am very pleased with the quality of the care I have been given. The staff is so caring and are supporting me in my care although I declined preventive chemotherapy and radiation. I am pleased to be allowed autonomy in my decision.
The first person that came in (np?) was very thorough and listened to all my questions and concerns. The doctor was great and patient and seemed to be able to be direct with me which is what I needed, answered my mothers emotional questions in a way she needed and spoke with my nurse sister in medical terms the way she needed. It was calming in what was a scary conversation for me without being condescending.
I always a positive experience with Dr. Cosgrove's team. Everyone is friendly and empathetic.
Dr Congrove was excellent.
Dr. Cosgrove is very caring. We discussed all options and we made the plan together. Things have improved for me because they worked hard and found the appropriate treatments. I'm very happy that I chose The James and that Dr. Cosgrove is my Oncologist!
Dr. Cosgrove is a amazing doctor . The James is lucky to have him. He saved my life!
Dr. Cosgrove and all the staff made me feel very comfortable. Dr Cosgrove spent time explaining everything and showing me the CT films
Feel very confident in the Dr. I feel I am in good hands at James.
The medical team is incredible!
Took his time to explain my condition , treatment and outcome. My trust increased in Dr Casey after my appt. Which is important as he will be the one performing an upcoming procedure.
He was open and confident
Dr. Cosgrove spent time with me and was very caring, making sure I was comfortable and well informed.
Couldn't ask for a better person.
Dr. Cosgrove treats each patient as if they are his only one he is absolutely the best doctor
Great. Seemed very concerned and helpful
Dr. Cosgrove is so amazing at making me feel he is doing everything to treat me. I feel relieved that he and his team are taking amazing care of me.
Very thankful to have been treated by this physician
Have all my trust in our Dr. And staff
Excellent care!
Dr. Cosgrove & staff - outstanding!
Dr. Cosgrove was amazing and took great care of me.
Great care very understanding couldn't ask for any better. Dr. Casey Cosgrove cares about his patients.
I am pleased with the service received.